DaBomb Protein Biotech Corp. (6578.TWO)
TWD 19.2
(-2.54%)
TWD 19.2
(-2.54%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 6.5 Million | 19.7 Million | -44.25 Million | 13.41 Million | - |
| Net Income | -55.94 Million | -49.05 Million | -71.61 Million | 11.63 Million | - |
| Depreciation & Amortization | 21.71 Million | 26.98 Million | 26.23 Million | 25.6 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 1.78 Million | 2.8 Million | 6.03 Million | - | - |
| Change in working capital | 10.69 Million | 37.06 Million | -2.55 Million | -20.19 Million | - |
| Other non-cash items | 1.72 Million | 2.91 Million | 2 Million | -250 Thousand | - |
| Investing Cash Flow | -31.89 Million | 12.95 Million | -382.75 Million | -63.48 Million | - |
| Investments in PPE | -18.87 Million | -20.15 Million | -332.09 Million | -18.31 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -12.55 Million | - | -21.82 Million | -45.48 Million | - |
| Sales/Maturities of investments | 752 Thousand | 32.89 Million | - | - | - |
| Other Investing Activities | -468 Thousand | 175 Thousand | -28.83 Million | 310 Thousand | - |
| Financing Cash Flow | 208.85 Million | -34.14 Million | 356.71 Million | 112.43 Million | - |
| Debt repayment | -29.66 Million | -119.24 Million | -351.03 Million | -128.43 Million | - |
| Dividends payments | -39.71 Million | - | -6.02 Million | -14.68 Million | -23.39 Million |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 277.6 Million | 86.3 Million | 13.19 Million | 252 Thousand | - |
| Other Financing Activities | -37.71 Million | - | 13.19 Million | - | - |
| Accounts receivables | -13.53 Million | - | - | - | - |
| Accounts payables | -19.3 Million | - | - | - | - |
| Inventory | 32.17 Million | -14.84 Million | 17.35 Million | -12.85 Million | - |
| Other working capital | -7.94 Million | - | - | - | - |
| Cash at beginning of period | 195.17 Million | 197.13 Million | 265.6 Million | 206.35 Million | - |
| Cash at end of period | 379.98 Million | 195.17 Million | 197.13 Million | 265.6 Million | - |
| Capital Expenditure | -18.87 Million | -20.15 Million | -332.09 Million | -18.31 Million | - |
| Effect of forex changes on cash | 1.33 Million | -473 Thousand | 1.82 Million | -3.1 Million | - |
| Net cash flow / Change in cash | 184.8 Million | -1.95 Million | -68.47 Million | 59.24 Million | - |
| Free Cash Flow | -12.36 Million | -449 Thousand | -376.34 Million | -4.89 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 7.09 Million | 8.69 Million | -55.94 Million | -4.07 Million | -27.11 Million | -10.68 Million |
| Depreciation & Amortization | 3.47 Million | 3.39 Million | 21.71 Million | 3.4 Million | 4.48 Million | 6.83 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 91 Thousand | 90 Thousand | 1.78 Million | 230 Thousand | 367 Thousand | 784 Thousand |
| Change in working capital | -4.7 Million | 5.98 Million | 10.69 Million | -14.74 Million | 7.26 Million | 25.17 Million |
| Other non-cash items | -1.13 Million | 1.26 Million | 1.72 Million | 648 Thousand | -321 Thousand | -981 Thousand |
| Investing Cash Flow | -11.42 Million | -1.11 Million | -31.89 Million | 398 Thousand | -16.7 Million | -1.19 Million |
| Investments in PPE | -1.91 Million | -1.19 Million | -18.87 Million | -965 Thousand | -15.73 Million | -1.1 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -9.46 Million | -1.13 Million | -12.55 Million | 1.29 Million | -1.51 Million | 989 Thousand |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -34 Thousand | 1.22 Million | -468 Thousand | 69 Thousand | 688 Thousand | - |
| Financing Cash Flow | -29.53 Million | -23.44 Million | 208.85 Million | -42.43 Million | -68.91 Million | 282.4 Million |
| Debt repayment | -29.1 Million | -23.1 Million | -29.66 Million | -42.1 Million | -28.85 Million | -5.14 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 277.6 Million | - | - | 277.6 Million |
| Other Financing Activities | -428 Thousand | - | -37.71 Million | - | -39.71 Million | - |
| Accounts receivables | -2.28 Million | - | - | - | - | - |
| Accounts payables | 2.8 Million | - | - | - | - | - |
| Inventory | -4.17 Million | -8.11 Million | 32.17 Million | -3.43 Million | 13.95 Million | 15.5 Million |
| Other working capital | -848.99 Thousand | - | - | - | - | - |
| Cash at beginning of period | 373.21 Million | 379.98 Million | 195.17 Million | 434.62 Million | 512.01 Million | 207.04 Million |
| Cash at end of period | 337.17 Million | 373.21 Million | 379.98 Million | 379.98 Million | 434.62 Million | 512.01 Million |
| Capital Expenditure | -1.91 Million | -1.19 Million | -18.87 Million | -965 Thousand | -15.73 Million | -1.1 Million |
| Effect of forex changes on cash | -731 Thousand | -1.42 Million | 1.33 Million | 1.53 Million | -2.04 Million | 2.09 Million |
| Net cash flow / Change in cash | -36.04 Million | -6.76 Million | 184.8 Million | -54.64 Million | -77.38 Million | 304.96 Million |
| Free Cash Flow | 3.71 Million | 18.01 Million | -12.36 Million | -15.1 Million | -5.45 Million | 20.55 Million |
ORA
IIJIF
6346
UNCRY
ATONY
ATOS